-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
CPI-818 is a first-in-class, oral inhibitor that potently inhibits ITK kinase.
Dr.
Director of the Chinese Society of Clinical Oncology (CSCO) , Secretary General of the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology (CSCO ) , China's leading researcher of the CPI-818-001 clinical trial, and Professor Song Yuqin, Department of Lymphoma, Peking University Cancer Hospital, said : "China is the world's In countries with a large number of T-cell lymphoma patients within the scope, the current five-year survival rate of patients with relapsed/refractory T-cell lymphoma is only 10-30%, which is an urgent clinical need